AzTrials
AzTrials

OsteonecrosisPhase 1/2NCT04233125

Core Decompression With or Without Cement Packing for ONFH

A Phase 1/2 study testing Core Decompression and PMMA augmentation in people with Osteonecrosis, run by University of Minnesota.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Osteonecrosis of the femoral head (ONFH) is difficult to treat as collapse frequently occurs after core decompression (CD). This may be due to the failure to provide structural support during revascularization and healing. Read more about this study

Who is it for?
Ages 14 years and older
Conditions the study is for
Osteonecrosis
What is being tested?
Core Decompression and PMMA augmentation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
37 participants
Where
No sites listed yet
Study dates
1 Jan 1997to 1 Jan 2008
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 14 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Association Research Circulation Osseous (ARCO) Stage I and II ONFH diagnosed using MRI and radiographic imaging

Who cannot join

  • pre-existing collapse, subchondral fracture or degenerative changes of the hip

About this study

Official title: A Randomized Controlled Trial of Core Decompression With or Without Cement Packing for Osteonecrosis of the Femoral Head - Long Term Results

Osteonecrosis of the femoral head (ONFH) is difficult to treat as collapse frequently occurs after core decompression (CD). This may be due to the failure to provide structural support during revascularization and healing. Reports of polymethylmethacrylate (PMMA) packing of the femoral head after CD for ONFH have noted favorable results. This study was undertaken to determine whether the addition of PMMA packing to CD provides any benefit to progression-free survival (PFS) and conversion to total hip arthroplasty-free survival (CFS). Secondary objectives were to assess for differences in functional outcomes and predictive factors for progression of the disease.

Read the detailed description

A prospective randomized controlled trial comparing the results of CD vs. CD + PMMA packing in pre-collapse ONFH was set up.

Consecutive symptomatic patients aged >14 years with Association Research Circulation Osseous (ARCO) Stage I and II ONFH diagnosed using MRI and radiographic imaging were enrolled in this study.

Exclusion criteria were pre-existing collapse, sub-chondral fracture or degenerative changes of the hip.

After obtaining informed written consent, patients are asked to complete the Harris Hip Score (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and a health status questionnaire Short Form-36 (SF-36).

The femoral heads enrolled into the study are randomized using a computer-generated card draw system to one of following: core decompression (CD) or core decompression with PMMA cement packing (CD + PMMA).

Allocation concealment was practiced with the use of opaque envelopes. Patients with bilateral involvement who had been randomized to one treatment modality for one femoral head were automatically selected to receive the other treatment modality for the contralateral femoral head.

Blinding of either surgeon or patient is impossible.

The patients were followed up after surgery every 3-4 months for the first 2 years after which the patients were seen annually. Completed questionnaires and radiographs were obtained at each visit.

Statistical Analysis The date of index procedure (CD or CD + PMMA) was used as start date for the purpose of statistical analysis. Progression Free Survival was defined as the time to radiographic progression and Conversion Free Survival (CFS) as the time to a THA. In case of patients who did not have radiographic progression, the date of their last follow up or death was used for the analysis. The SAS software will be used for all the analyses. The Log rank and Gerhan-Wilcoxon tests were used to compare Kaplan-Meier survival curves for the time from the date of the index procedure to radiographic progression (subchondral collapse) or conversion to THA for separate groupings based on age at index procedure (<40 , >40 yrs), smoking (Y/N), location (central, medial, lateral), percent involvement (<15% [mild], 15% to 30% [moderate], or >30% [severe]), index of necrotic extent (<40 or >40), and modified index of necrotic extent (<40 or >40). Whenever factors were found to affect the survival curves mainly in the initial year the Gerhan-Wilcoxon test was used as the test of significance. The Kaplan-Meier curves were also compared for the main cohorts of CD vs. CD + PMMA. Cox proportional hazards regression was used to compare factors (age, smoking, location, percent involvement, index of necrotic extent, and modified index of necrotic extent) with regards to their ability to predict the time to progression or revision to THA. Mixed multilevel regression modeling was used to test for group differences in the change in self-rated health survey scores over time from baseline over the post-operative period. The hierarchical linear modeling approach has a number of advantages over traditional repeated measures approaches for modeling change over time, including allowance for missing data and for varying measurement times across subjects. Separate models were generated for SF-36, Harris Hip Score and WOMAC scores over two-year and over 5-year post-operative time periods.

Conditions
Osteonecrosis
Being tested
Core Decompression, PMMA augmentation
Keywords
Femoral Head, Hip, Core Decompression, Polymethlymethacrylate, Cement, Progression, Survival
Medical subject headings
Osteonecrosis, Disease Progression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Core DecompressionProcedure or surgery

    Core Decompression

  • PMMA augmentationProcedure or surgery

    Polymethylmethacrylate (PMMA) augmentation

Study groups in NCT04233125
Study groupRoleWhat they receive
Core Decompression (CD) OnlyActive comparatorParticipants in this group receive standard care
Receives: Procedure: Core Decompression
Added Polymethylmethacrylate (PMMA)ExperimentalParticipants in this group receive standard care with an additional treatment
Receives: Procedure: Core Decompression; Procedure: PMMA augmentation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as the length of time (reported in months) following surgery that participants have no signs of radiographic progression of femoral head osteonecrosis. Radiographic progression is defined as any degree of flattening or loss of spherical contour of the femoral head as detected on the radiographs or MRI. Appearance of a subchondral fracture (crescent sign) on radiographs or MRI was also considered a sign of progression.

    Measured: 5 years

Secondary outcomes (7)
  1. Conversion Free Survival (CFS)

    Conversion Free Survival (CFS) is defined as the length of time (reported in months) following surgery that participants are able to live without surgical conversion to total hip arthroplasty (THA).

    Measured: 5 years

  2. Mean Harris Hip Score (HHS)

    The Harris Hip Score (HHS) is a clinician-based instrument with 4 sub-scales measuring pain severity (44 points), function (47 points), absence of deformity (4 points), and range of motion (5 points). Total score is calculated as a sum of 4 sub-scale scores and ranges from 0-100 with higher scores representing less dysfunction. Three time points will be reported.

    Measured: baseline, 2 years post surgery, 5 years post surgery

  3. Change in Harris Hip Score (HHS)

    The Harris Hip Score (HHS) is a clinician-based instrument with 4 sub-scales measuring pain severity (44 points), function (47 points), absence of deformity (4 points), and range of motion (5 points). Total score is calculated as a sum of 4 sub-scale scores and ranges from 0-100 with higher scores representing less dysfunction.

    Measured: baseline, 2 years post surgery

  4. Mean Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a self-administered questionnaire consisting of 24 items divided into 3 subscales: Pain (5 items), stiffness (2 items), and physical function (17 items). Items are rated on a Likert scale of 0 (extreme) to 4 (none). Raw sub-scale scores are normalized by multiplying each score by 100/96. Total scores are a sum of the normalized sub-scales scores and range 0-100, with higher scores indicating better functioning. Three time points will be reported.

    Measured: baseline, 2 years post surgery, 5 years post surgery

  5. Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a self-administered questionnaire consisting of 24 items divided into 3 subscales: Pain (5 items), stiffness (2 items), and physical function (17 items). Items are rated on a Likert scale of 0 (extreme) to 4 (none). Raw sub-scale scores are normalized by multiplying each score by 100/96. Total scores are a sum of the normalized sub-scales scores and range 0-100, with higher scores indicating better functioning.

    Measured: baseline, 2 years post surgery

  6. Mean Short Form-36 (SF-36)

    The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health, containing 8 scaled sub-scores: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each sub-scale score is calculated as the weighted sum of the questions in that section, then directly transformed into a 0-100 score using a scoring algorithm. The SF-36 also produces two summary scores, physical component summary and the mental component summary. Lower scores indicated greater disability. Three time points will be reported.

    Measured: baseline, 2 years post surgery, 5 years post surgery

  7. Change in Short Form-36 (SF-36)

    The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health, containing 8 scaled sub-scores: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each sub-scale score is calculated as the weighted sum of the questions in that section, then directly transformed into a 0-100 score using a scoring algorithm. The SF-36 also produces two summary scores, physical component summary and the mental component summary. Lower scores indicated greater disability.

    Measured: baseline, 2 years post surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jan 2020
  2. Study start1 Jan 1997
  3. Primary completion1 Jan 2005
  4. Study completion1 Jan 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
37 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04233125
Sponsor's protocol ID
9604M11032
Status last verified
Jan 2020
First submitted
14 Jan 2020
Last updated
18 Jan 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Core Decompression and PMMA augmentation in people with Osteonecrosis, run by University of Minnesota.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression Free Survival (PFS) (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2020; AzTrials last refreshed its copy on 28 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in